Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine

Joseph P. Casazza(The University of Texas Southwestern Medical Center), Anita Arthur(National Institutes of Health), Nina M. Berkowitz(National Institutes of Health), Abidemi Ola(National Institute of Allergy and Infectious Diseases), Pamela Costner(National Institutes of Health), William R Whalen(National Institutes of Health), Jennifer Cunningham(National Institute of Allergy and Infectious Diseases), Richard A. Koup(Aaron Diamond AIDS Research Center), Barney S. Graham(National Institutes of Health), Alicia T. Widge, Lesia Dropulic(National Institutes of Health), Preeti Apte(National Institutes of Health), Manjula Basappa(National Institutes of Health), Laura Novik(National Institutes of Health), Kevin Carlton(National Institute of Allergy and Infectious Diseases), Diane Wycuff(National Institutes of Health), Sandra Vazquez(National Institutes of Health), Galina V. Yamshchikov(National Institutes of Health), Sarah F. Andrews(National Institutes of Health), Theodore C. Pierson(National Institutes of Health), Adrian Creanga(National Institute of Allergy and Infectious Diseases), Masaru Kanekiyo, Hillary A. Vanderven(Australian Institute of Tropical Health and Medicine), Mike Castro(National Institutes of Health), Jamie Saunders(National Institutes of Health), Ingelise J. Gordon(National Institute of Allergy and Infectious Diseases), Sandeep Narpala(National Institutes of Health), Marjaan Imam(National Institute of Allergy and Infectious Diseases), Leonid Serebryannyy(National Institutes of Health), John R. Mascola(National Institute of Allergy and Infectious Diseases), Katherine V. Houser(National Institutes of Health), Rebecca A. Gillespie(National Institutes of Health), Amelia R. Hofstetter(National Institutes of Health), Jason G. Gall(GenVec), Julie E. Ledgerwood(Vaccine Research Institute of San Diego), Maria Claudia Burgos Florez(National Institutes of Health), Jessica F. Trost(National Institutes of Health), Cynthia S. Hendel(National Institutes of Health), Ana M. Ortega‐Villa(National Institutes of Health Clinical Center), Mursal Naisan(National Institutes of Health), Lu Wang(Children's Hospital of Philadelphia), Xiaolin Wang, William C. Adams(Program for Appropriate Technology in Health), Richard L Wu(National Institute of Allergy and Infectious Diseases), Larisa Strom(National Institute of Allergy and Infectious Diseases), LaSonji A Holman(National Institute of Allergy and Infectious Diseases), Floreliz Mendoza(National Institutes of Health), Adrian B. McDermott, Sarah H. Plummer(National Institutes of Health)
npj Vaccines
September 17, 2024
Cited by 22


Related Papers